BLFS BIOLIFE SOLUTIONS INC Insider Trading

Casdin Partners (10% owner) sells 1,200,000 shares across 3 trades for $28,125,000.00; holdings drop to 4.76M shares (-20.1%).

Casdin Partners Master Fund, LP, a 10% stakeholder, executed 3 separate sales totaling 1,200,000 shares for $28,125,000.00 at a blended average price of $23.44 over three consecutive trading days (May 19–21, 2026), reducing holdings from 5.96M to 4.76M shares. The insider's prior sale at BLFS on 2025-10-15 showed a 90d return of -16.3%, demonstrating a 100.00% well-timed rate at this ticker. The company remains unprofitable on a full-year basis despite quarterly revenue of $27,500,000.00 and annual revenue growth of +17.0%, creating a disconnect between top-line momentum and bottom-line profitability that warrants investor attention. At the current price of $24.74, the stock is +10.6% over 30 days and -16.5% from its 52-week high, placing this sale within a period of near-term strength but medium-term weakness.

Chief Quality & Operations Officer Karen A. Foster sells 97,423 shares (46.2% of holdings) for $1,962,998.45 in 2 transactions.

Karen A. Foster, Chief Quality and Operations Officer, executed 2 separate sales totaling 97,423 shares for $1,962,998.45, reducing her holdings from 210,665 shares to 113,242 shares—a 46.2% reduction in her stake. The sales occurred at a blended average price of $20.15, which is 1.3% above the current price of $19.90 but 30.9% below the 52-week high of $28.79, indicating the stock has declined substantially from recent highs. This is a material reduction in insider ownership by a C-suite executive during a period when the company is trading at a compressed valuation (P/E of 76.54) against mixed fundamentals: while annual revenue growth is solid at 17.0%, the company was unprofitable over its most recent full fiscal year and the stock has fallen 11.3% in the past 30 days and 19.6% over 90 days. The magnitude of the sale—nearly half her holdings liquidated in two transactions over four days—represents a significant shift in insider exposure to the company.

CFO Wichterman sells 30,000 BLFS shares at $25.72; company facing -42.6% annual revenue decline and full-year unprofitability

Wichterman, CFO of BioLife Solutions, sold 30,000 shares (30.0K shares) at $25.72 on 2025-12-04, reducing his holdings by 16.4% to 152.8K shares and generating $771.6K in proceeds. The sale occurs in a context of material operational headwinds: annual revenue growth contracted -42.6% and the company posted negative net income over its most recent full fiscal year. His prior sell at this ticker on 2025-04-01 was followed by a 90-day return of -4.9%, marking a well-timed exit before a post-sale decline. The current trading environment shows the stock at $25.46, down 7.6% over the past 30 days, suggesting ongoing price pressure. A CFO's reduction of roughly one-sixth of his holdings during a period of significant revenue contraction and full-year unprofitability warrants investor attention to the underlying business trajectory.

BLFS CEO DE GREEF RODERICK sells 100,000 shares (20.4% of holdings) across 3 trades for $2.6M at blended avg $25.80; stock -9.1% in 30 days.

DE GREEF RODERICK, President and CEO of BioLife Solutions, executed 3 separate sales totaling 100,000 shares ($2,580,421.84) over three trading days (Nov 11–13, 2025) at prices ranging from $26.15 to $25.33, reducing his holdings by 20.4% from 490,000 to 390,000 shares. The timing of this substantial liquidation is noteworthy against the company's fundamental backdrop: annual revenue declined 42.6% year-over-year, the company was unprofitable over its most recent full fiscal year, and the stock has fallen 9.1% over the past 30 days and is now 12.7% below its 52-week high. His prior sale at this ticker on 2024-10-31 showed a positive 90-day return of +20.8%, indicating that prior sale was poorly-timed relative to subsequent stock appreciation. The current significant reduction in CEO stake combined with negative revenue trends and unprofitable operations may merit close examination of operational and strategic developments.

Casdin Partners (10% owner) sold 750,000 shares of BLFS at $28.55 on 2025-10-15; now holds 5.96M shares.

Casdin Partners, a 10% shareholder, sold 750,000 shares (-11.2% of prior holdings) near the 52-week high ($28.55 vs $28.75 peak). The company faces significant fundamental headwinds: annual revenue declined 42.6% and net income was negative $15,838,000.00 on quarterly revenue of $25,421,000.00. At the same ticker, Casdin's prior three trades show a mixed pattern: two recent sells in August (30d returns +4.6% and +17.2%) and a June sell that returned -4.5% over 30 days but +10.2% over 90 days, with zero of one measurable sells well-timed at the 90-day mark. The sale occurs after a +31.2% 90-day rally, reducing concentrated exposure in a fundamentally challenged company while the stock remains near recent peaks.

Casdin Partners (10% owner) sells 500.0K BLFS shares at $24.40; stock now $25.08 amid -42.6% annual revenue decline.

Casdin Partners sold 500,000 shares of BIOLIFE SOLUTIONS at $24.40 on 2025-08-15, reducing holdings by -6.9% from 7,207,165 to 6,707,165 shares. This is the fund's second sale at BLFS in five days (prior sell on 2025-08-11), suggesting deliberate liquidation activity near the current price of $25.08, which is -12.0% from the 52-week high. The company faces significant operational headwinds: revenue declined -42.6% year-over-year and the business is unprofitable with net income of $-15,838,000 on quarterly revenue of $25,421,000. Casdin's cross-ticker track record shows only 2 prior sells with an average 30-day return of -4.5%, a limited sample; the prior BLFS sale on 2025-06-10 posted a -4.5% 30-day return, though longer-term outcomes remain unmeasurable. The timing and concentration of recent liquidation against deteriorating financial fundamentals are relevant context for investors monitoring this position.

Casdin Partners (10% owner) sold 500,000 shares of BLFS at $22.60 on 2025-08-11 for $11.3M, retaining 7.21M shares.

Casdin Partners sold 500,000 shares (approximately 6.5% of its pre-transaction holdings) at $22.60, reducing its stake to 7.21M shares while the stock now trades at $25.68. The sale occurred at the lower end of the 52-week range ($20.47–$28.49), and within 90 days the stock has risen 16.8%, suggesting the timing was not favorable for the selling insider. BLFS faces fundamental headwinds: revenue declined 42.6% year-over-year to $25.4M in the latest quarter, the company posted a $-15.8M net loss, and annual results were unprofitable. The insider's cross-ticker track record shows 1 prior sell with a -4.5% 30-day return, though the 90-day outcome from that BLFS sale on 2025-06-10 is not yet measurable. This partial reduction occurs against deteriorating operational performance rather than at a peak, and the subsequent price appreciation indicates the market has moved counter to the insider's directional signal.

Casdin Partners (10% owner) sold 1,000,000 shares of BLFS at $23.80; holds 7.71M shares post-transaction. Stock down 18.2% from 52-week high.

Casdin Partners' 1,000,000-share sale represents an 11.5% reduction in its BLFS holdings, executed at $23.80 per share, a price that now sits 18.2% below the 52-week high of $28.49. The company's fundamentals are concerning: annual revenue contracted 42.6%, the most recent quarter generated only $23.9M in revenue against a $-448.0K net loss, and the firm was unprofitable over its most recent full fiscal year. Casdin's cross-ticker track record shows 20 prior open-market transactions with a 40.00% 90-day win rate and negative average 90-day returns of -0.4%, indicating modest timing precision historically. This sale by a significant stakeholder, combined with deteriorating operational metrics and the stock's weakness below its annual range, merits investor attention to near-term catalysts and management guidance.